Abbott to Pay $670 Million to Settle Baby-Formula Litigation

Recent reporting across major financial and legal news outlets details a significant financial resolution concerning specialty infant nutrition products. Abbott has reached agreements to resolve a portion of ongoing litigation involving its specialty formulas for preterm infants, specifically addressing lawsuits related to necrotizing enterocolitis. Coverage from Bloomberg indicates that this payment amounts to $670 million and is intended to end approximately 2,000 infant formula claims. Additional details regarding the scope of the agreements appear in reports from PR Newswire, Abbott MediaRoom, TradingView, and Kalkine Media, which outline the corporate response to the legal pressure. The unfolding situation has drawn substantial coverage from a diverse group of publications, emphasizing both the corporate financial measures and the broader legal context surrounding infant formula makers.

Outlets including the Wall Street Journal, Reuters, ET HealthWorld, Drugwatch.com, qz.com, and the UnionLeader.com have all tracked the developments closely. According to Reuters, the settlement announcements coincide with separate legal actions, noting that Abbott also settled an appeal over a previous infant formula verdict valued at $495 million. Meanwhile, Law.com reports that the settlement announcement arrived precisely as the first federal formula trial began against a competitor, Mead Johnson. This litigation centers primarily on specialty formulas utilized for preterm infants, with specific focus directed toward NEC, or necrotizing enterocolitis, a severe gastrointestinal condition affecting newborns. The coverage highlights that Similac maker Abbott faced extensive court battles involving thousands of individual claims asserting links between its specialty products and the development of the condition.

While the current agreements resolve a substantial portion of the pending caseload against Abbott, the broader legal landscape involving infant formula manufacturers remains active and heavily scrutinized by legal analysts and industry watchers as trials commence in federal courts. As the legal proceedings continue to unfold across multiple jurisdictions, observers are monitoring how these resolution agreements will impact the remaining unresolved claims and ongoing trials. Coverage does not yet specify the full mechanics of how the $670 million will be distributed among the claimants, nor does it detail the exact terms of the appeal settlement regarding the separate $495 million verdict. Future updates from Reuters, Bloomberg, the Wall Street Journal, and legal reporting platforms are expected to track the ongoing federal trials involving Mead Johnson and any subsequent developments regarding Abbott's remaining legal exposure.